HPV Cancer: Vaccine and Profit

Not as effective as they make it out to be.

• HPV vaccine is injecting 1,500 mcg of aluminum over a period of less than a year via 3 doses of Gardasil 9. 
• The trials statistics reflect there is the potential of 2,300 serious adverse events to try and prevent 7.9 cases of cervical cancer. Adverse event reports show this vaccine is devastating. 61,552 cases of vaccine injury from the HPV vaccine. That’s more than the total number of cervical cancer in the United States in any given year.

The Risk of Cancer has been low and not decreased significantly after vaccine marketing

The proven way to prevent cancer is early detection. Because precancerous lesions found by Pap smears can be treated and cured before they develop into cancer, and because cervical cancer is often detected before it becomes advanced, the incidence and death rates for this disease are relatively low. 

*According to data for the period from 2003 through 2007, the incidence rate for cervical cancer was 8.1 cases per 100,000 women per year in the United States. 10 years later, after the advent of the vax the rate averages at 7.8 per 100,000.  

The mortality rate 10 years ago was 2.4 deaths per 100,000 women per year. In 2010, an estimated 12,200 women in the United States will be diagnosed with cervical cancer, and an estimated 4,210 will die of the disease. 

In 2016, the death rate averages 2.3. 

This chart created by the CDC does NOT show a significant decline in cancer deaths even though vaccines were introduced in 2004, 2009 and 2014 with that implied they would reduce the risk. 

Notice the above rates have not decreased with any great significance even though the CDC reports that 6 in 10 girls and 5 in 10 boys are getting the vaccine series.

The Risk of the new vaccine.

For the first time, Merck has disclosed what may indeed be close to the true rate of serious adverse events people are suffering after the use of Gardasil and will probably continue to suffer if they consent to using Gardasil 9. The only difference would be that the rates may be higher when used in the general population because certain at-risk groups are excluded from clinical trial participation but not from vaccination programs.

2.3-2.5% doesn’t sound that bad until you compare apples to apples. Cervical cancer rates are always quoted as # per 100,000. Given the above information, for every 100,000 people using Gardasil 9 there would be 2,300 serious adverse events. The cervical cancer diagnosis rate in the United States is 7.9/100,000.

What health official in their right mind is willing to anticipate 2,300 serious adverse events to try and prevent 7.9 cases of cervical cancer?

Keep in mind that the cost of vaccinating 100,000 people is around $30 million ($100 per injection, 3 injections). This doesn’t even begin to address the cost of treating 2,300 serious adverse events, the emotional, physical and financial expense to families and the cost to society via the lost productivity of the injured.

*Men do not get cervical cancer – the vac is recommended for boys 9 years old. Could that be because it’s one of the most profitable products for manufacturers?

All About Profit

The rise in the number of mergers and acquisitions and strategic collaborations are estimated to offer lucrative opportunities for the market players in the next few years. Some of the key players operating in the vaccines market across the globe are Merck & Co., Inc., CSL Ltd, GlaxoSmithKline plc., Janssen Pharmaceutical Company, Pfizer, Inc., Sanofi Pasteur SA, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Ltd, Emergent BioSolutions Inc.,And Novavax AB.

https://www.transparencymarketresearch.com/global-vaccine-market.html

Additional Articles:

Gardasil 9 – Important information

Gardasil 9 increases aluminum content There is absolutely no excuse for exposing young women and men to this level of risk for a vaccine that provides nothing other than promises of results far down the road.

Oncology Dietitian Exposes Fraud in CDC’s HPV Vaccine Effectiveness Study

Recent reductions in HPV infection prevalence among young women in the US cannot be said to be due to introduction of Gardasil vaccine in 2006 and use of HPV vaccines by pre-teen and teenage girls since then; the data clearly shows that unvaccinated girls had the best outcome https://articles.mercola.com/sites/articles/archive/2013/07/16/hpv-vaccine-effectiveness.aspx

Developer of Vaccine says its ALL RISK no benefit

The HPV vaccine was NEVER developed to prevent cancer, it was developed and approved to prevent WARTS. Warts are not a public health threat.